doi:10.4166/kjg.2011.57.5.330

Journal List > Korean J Gastroenterol > v.57(5) > 1006816

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Posttransplantation Prophylaxis with Primary High-dose Hepatitis B Immunoglobulin Monotherapy and Complementary Preemptive Antiviral Add-on. Liver Transpl 2011;17: 456–465

Research Update

Korean J Gastroenterol 2011;57(5):330-331.

Published online: 4 October 2011

DOI: https://doi.org/10.4166/kjg.2011.57.5.330

Posttransplantation Prophylaxis with Primary High-dose Hepatitis B Immunoglobulin Monotherapy and Complementary Preemptive Antiviral Add-on. Liver Transpl 2011;17: 456–465

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Hwang S, Ahn CS, Song GW, et al. Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. Liver Transpl. 2011; 17:456–465.

2. Hwang S, Lee SG, Ahn CS, et al. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl. 2008; 14:770–778.

3. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005; 11:716–732.

4. Yi NJ, Suh KS, Cho JY, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2007; 13:451–458.

5. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008; 134:1890–1899.

6. Lupo J, Larrat S, Hilleret MN, et al. Assessment of selective re-al-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J Virol Methods. 2009; 156:52–58.

7. Song DE, Jung DH, Hwang S, Park BH, Yu E. Characterization of histopathological features that differentiate hepatitis B virus infection from acute cellular rejection. Korean J Pathol. 2009; 43:535–541.

8. Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: metaanalysis. Clin Gastroenterol Hepatol. 2008; 6:696–700.

9. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008; 2:147–151.

10. Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl. 2009; 15:413–420.

Go to :

TOOLS

Similar articles